Key Highlights

  • Quanterix (NASDAQ:QTRX) closed at USD 2.73 on September 8, 2026 and traded near USD 3.18 on October 8, and a published screen shows a one-month gain of 19.70%, after a USD 3.81 close on October 5.
  • On September 14, 2026 Quanterix named Dr. Yuri Fesko chief medical officer to support the Lucent AD Complete five-biomarker Alzheimer's test and the in vitro diagnostic filing for its HD-X instrument.
  • The stock rose 6.7% on September 16, when it reported inducement Equity grants including 260,315 restricted stock units to its chief commercial officer, James Gute, and 365,326 units to two other employees.
  • On October 7, 2026 Quanterix and Innovita announced Chinese NMPA approvals for Simoa technology and testing, yet Quanterix (NASDAQ:QTRX) fell 4.96% by October 8 on the screener.

Product and Hiring News

Quanterix makes Simoa, an ultrasensitive technology that detects very low levels of proteins in blood and tissue. On September 14, 2026 it hired Dr. Yuri Fesko as chief medical officer to help launch the Lucent AD Complete five-biomarker Alzheimer's test and file the HD-X instrument for in vitro diagnostic clearance. On September 25 it said PhenoCode 2.0 Molecular Barcoding Kit was released globally and that its TIME panel and high-plex antibody-drug-conjugate panel will ship in the fourth quarter of 2026, and the stock rose 2.83% that day. Closes climbed from USD 2.50 on September 14 to USD 3.52 on September 28. Simoa is the company's core platform.

China Approvals

On October 7, 2026 Quanterix and Innovita announced approvals from China's National Medical Products Administration for Simoa technology and testing, expanding access to in vitro diagnostic use in China. A regulatory approval can open a large market, but the release gave no Revenue estimates. The stock had closed at USD 3.81 on October 5, its highest close of the month, then slipped to about USD 3.34 on October 7 and USD 3.18 on October 8 per the screener, so the approval did not extend the rally. Canaccord cut its target to USD 3 from USD 4 around August 20, which shows how cautious analysts had been. China is a large diagnostics market, though the release did not size the opportunity.

Risks and What to Watch

The stock is up about 20% in a month but down sharply over a year, with a 52-week range of USD 2.15 to USD 8.77 and a Market Value near USD 149 million, so it sits near the low end. The screener shows a Return on Equity of negative 46.49%, and the company still depends on launches for growth. Equity inducement grants add dilution, and diagnostics approvals take time to convert into revenue. Watch for the fourth quarter shipments of new panels, the HD-X filing and the third quarter report, estimated for November 9, 2026. The Negative return on equity suggests continuing losses, so cash runway and financing will also matter. The HD-X filing and fourth quarter panel shipments are the clearest near-term steps.

Where Things Stand

Quanterix (NASDAQ:QTRX) rose about 20% in a month because of a steady stream of product, hiring and regulatory news, including the October 7 China approvals. The stock fell after that news, and it remains near the lower half of its 52-week range with large losses. Revenue proof from the Alzheimer's test and the HD-X filing will matter more than headlines. Watch the November 9 estimated report. Quanterix (NASDAQ:QTRX) needs revenue proof.